SB66 revises Kentucky’s DUI and implied-consent laws. It restates the prohibited conduct for operating or being in physical control of a motor vehicle while impaired by alcohol, drugs, or a combination of substances, and it keeps the existing 0.08 blood-alcohol standard, the 0.02 standard for drivers under 21, and the controlled-substance provisions. The bill also preserves the current penalty structure for repeat offenses, including jail, fines, community labor, felony treatment for fourth or subsequent offenses, and enhanced mandatory minimums when aggravating circumstances are present.
The bill makes several procedural changes to chemical testing and evidence rules. It clarifies when blood or breath test results are admissible, expands and reorganizes the list of controlled substances relevant to drugged-driving prosecutions, and updates the warnings officers must give when requesting breath, blood, or urine tests. It also strengthens provisions for search warrants and court-ordered blood testing, especially in fatal crashes, and provides immunity protections for medical professionals and facilities that draw blood under a warrant or court order, absent gross negligence or willful misconduct.
SB66 also changes how the Transportation Cabinet maintains driving history records. It extends the retention period for moving traffic convictions from five years to ten years, requires indefinite retention for commercial driver’s license holders and applicants, and directs the cabinet not to release certain under-21 suspension records and to destroy those suspension records shortly after reinstatement. The bill also keeps the existing fee for driving history records and dedicates a portion to the state driver education program.
The overall sentiment reflected in the voting history is strongly supportive. The bill passed the Senate unanimously on third reading, later passed the House on a veto override with a substantial majority, and then passed the Senate again on the override vote without opposition. That pattern suggests broad bipartisan agreement on the bill’s core public-safety and enforcement goals.
The main points of contention, as reflected in the bill text rather than committee debate, are the balance between enforcement and individual rights. The bill expands the use of warrant-based blood testing, requires officers to seek a warrant in fatal crashes unless testing was already done by consent, and preserves penalties for refusal to test, which may raise concerns about privacy, bodily autonomy, and due process. At the same time, it includes protections for prescribed controlled substances, limits admissibility in some circumstances, and grants liability protections to medical personnel, indicating an effort to balance prosecution needs with medical and legal safeguards.
SB66 amends KRS 189A.010, KRS 189A.105, and KRS 186.018. Its practical effect is to update Kentucky’s DUI enforcement framework, clarify evidentiary rules for alcohol and drug testing, expand warrant-based blood draw procedures, and lengthen the retention of driving conviction records. It affects drivers, law enforcement, prosecutors, courts, medical professionals, and the Transportation Cabinet, while leaving the core DUI penalty scheme largely intact.
The bill appears to have enjoyed broad support and little visible opposition in floor votes. It passed the Senate 30-0 and later passed both chambers again during the veto-override process, including a 79-15 House vote and a 35-0 Senate vote. That voting pattern suggests the legislation was viewed as a public-safety measure with enough consensus to survive a veto.
The most notable tensions involve enforcement authority versus civil liberties. Supporters likely favored stronger tools for impaired-driving investigations, especially warrant-based blood testing in fatal crashes and clearer refusal penalties, while critics may have been concerned about compelled testing, expanded record retention, and the use of refusal or test results in court. The bill also distinguishes between illegal drug use and lawful prescription use, which helps address fairness concerns for medically authorized substances, but the broad testing and penalty provisions still reflect the central policy tradeoff.